Considerations for the treatment of multiple sclerosis in the managed care setting

Formulary

Volumn 38, Issue 11, 2003, Pages 646-655

  Morrow, Thomas ^a,b   Brown, Jean ^c   Smith, Craig ^d   Thrower, Ben ^e  

^a Matria Healthcare Inc   (United States)

^b Natl Assoc of Managed Care Phys   (United States)

^c United Drugs   (United States)

^d SWEDISH MEDICAL CENTER   (United States)

^e Shepherd Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; AMITRIPTYLINE; BACLOFEN; BETA1A INTERFERON; BISACODYL; CARBAMAZEPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONAZEPAM; DANTROLENE; DOCUSATE SODIUM; FLAVOXATE; FLUOXETINE; GABAPENTIN; GLATIRAMER; IMMUNOMODULATING AGENT; INTERFERON; INTERFERON BETA SERINE; MODAFINIL; MYELIN; OXYBUTYNIN; PEMOLINE; PHENYTOIN; PROPANTHELINE BROMIDE; PSYLLIUM HYDROCOLLOID; SENNA EXTRACT; TERIFLUNOMIDE; TIZANIDINE; TOLTERODINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

AMNESIA; BALANCE DISORDER; BLADDER DYSFUNCTION; BLOOD TOXICITY; CLINICAL FEATURE; COGNITIVE DEFECT; DEPRESSION; DISEASE COURSE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; EPIDEMIOLOGICAL DATA; FATIGUE; FECES INCONTINENCE; FLU LIKE SYNDROME; GAIT DISORDER; HEALTH CARE COST; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HUMAN; IMMUNOPATHOLOGY; INCONTINENCE; INJECTION SITE; INTERNET; LIVER TOXICITY; MANAGED CARE ORGANIZATION; MULTIPLE SCLEROSIS; PAIN; PATIENT EDUCATION; REVIEW; SEXUAL DYSFUNCTION; SPASTICITY; THYROID DISEASE; TREATMENT OUTCOME; TREMOR; VISUAL DISORDER;

EID: 0242721791     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Batavia AI, DeJong G. Disability, chronic illness, and risk selection. Arch Phys Med Rehabil. 2001;82:546-552.
2. Pope GC, Urato CJ, Kulas ED, et al. Prevalence, expenditures, utilization, and payment for persons with MS in insured populations. Neurology. 2002;58:37-43.
3. National Institute of Neurological Disorders and Stroke. Multiple sclerosis: Hope through research. Available at http://www.ninds.nih.gov/health_and_medical/pubs/multiple_sclerosis.htm. Accessed October 24, 2003.
4. Leary SM. Current management of multiple sclerosis. Int J Clin Pract. 2000;54:161-169.
5. Noseworthy JH, Lucchinetti C, Rodriguez M, et al. Multiple sclerosis. N Engl J Med. 2000;343:938-952.
6. Weinshenker BG, Bass B, Rice GPA, et al. The natural history of multiple sclerosis: A geographically based study, I: Clinical course and disability. Brain. 1989;112:133-146.
7. Willer CJ, Ebers GC. Susceptibility to multiple sclerosis: interplay between genes and environment. Curr Opin Neurol. 2000;13:241-247.
8. Polman CH, Uitdehaag BMJ. Drug treatment of multiple sclerosis. BMJ. 2000;321:490-494.
9. Halper J. Best practices in the nursing care of multiple sclerosis: Disease management, pharmacologic treatment, and nursing research. Presented at: 11th Annual Meeting of the European Neurological Society; April 21-25, 2001; Paris, France.
10. Munschauer FE III, Stuart WH. Rationale for early treatment with interferon beta-la in relapsing-remitting multiple sclerosis. Clin Ther. 1997;19:868-882.
11. Lublin FD, Reingold SC, for the National Multiple Sclerosis Society Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Defining the clinical course of multiple sclerosis: Results of an international survey. Neurology. 1996;46:907-911.
12. Costello K, Hill CA, Tranter MC. Multiple sclerosis in the primary care setting: Key issues for diagnosis and management. The American Journal for Nurse Practitioners. 2000;October:9-14, 17-18, 23-26.
13. Avonex [package insert]. Cambridge, Mass: Biogen, Inc; 2003.
14. Rebif [package insert]. Rockland, Mass: Serono, Inc; 2002.
15. Betaseron [Package Insert]. Montville, NJ: Berlex Laboratories; 2003.
16. Copaxone [package insert]. Kansas City, Mo: Teva Neuroscience, Inc; 2002.
17. Novantrone [package insert]. Seattle, Wash: Immunex Corp; 2002.
18. Salmon SE, Sartorelli AC. Cancer Chemotherapy. In: Katzung BG, ed. Basic & Clinical Pharmacology. 8th ed. New York, NY: Lange Medical Books/McGraw-Hill; 2001:943.
19. National Multiple Sclerosis Society-Sourcebook. Early intervention: Disease management consensus statement). Available at: http://www.na tionalmssociety.org/Sourcebook-Early.asp. Accessed October 24, 2003.
20. Johnson KP, Brooks BB, Ford CC, et al. Results of the long-term (eight-year) prospective, open-label trial of glatiramer acetate for relapsing multiple sclerosis [abstract]. Neurology. 2002;58 (Suppl 3):A458.
21. Goodin DS, Frohman EM, Garmany GP Jr, et al. Disease modifying therapies in multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology. 2002;58:169-178.
22. Traboulsee A, Li D, Frank J, et al. Consortium of MS Centers MRI protocol for the diagnosis and follow-up of MS. Teaneck, NJ: Consortium of MS Centers; 2003.
23. Freedman MS, Blumhardt LD, Brochet B, et al. International consensus statement on the use of disease-modifying agents in multiple sclerosis. Mult Scler. 2002;8:19-23.
24. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology. 1983;33:1444-1452.
25. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial. Neurology. 1995;45:1277-1285.
26. Paty DW, Li DKB, the UBC MS/MRI Study Group, et al. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis, II: MRI analysis results of a multicenter randomized, double-blind, placebo-controlled trial. Neurology. 1993;43:662-667.
27. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol. 1996;39:285-294.
28. PRISMS Study Group. Randomised, double-blind, placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet. 1998;352:1498-1504.
29. PRISMS Study Group. PRISMS-4: Long-term efficacy of interferon-β-1a in relapsing MS. Neurology. 2001;56:1628-1636.
30. Johnson KP, Brooks BR, Cohen JA, et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology. 1998;50:701-708.
31. Johnson KP, Brooks BR, Ford CC, et al. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Mult Scler. 2000;6:255-266.
32. Johnson KP, Brooks BB, Ford CC, et al. Results of the long-term (8-year) prospective, open label trial of glatiramer acetate for relapsing multiple sclerosis. Poster presented at: 54th Annual Meeting of the American Academy of Neurology; April 13-20, 2002; Denver, Colo.
33. Comi G, Filippi M, Wolinsky JS, et al. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol. 2001;49:290-297.
34. Filippi M, Rovaris M, Rocca MA, et al. Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes." Neurology. 2001;57:731-733.
35. Yong VW. Differential mechanisms of action of interferon-β and glatiramer acetate in MS. Neurology. 2002;59:802-808.
36. Martin R, Sturzebecher CS, McFarland HE. Immunotherapy of multiple sclerosis: Where are we? Where should we go? Nat Immunol. 2001;2:785-788.
37. Rosenberg GA, Dencoff JE, Correa N, et al. Effects of steroids on CSF matrix metalloproteinases in multiple sclerosis: Relation to blood-brain barrier injury. Neurology. 1996;46:1626-1632.
38. Waubant E, Goodkin DE, Gee L, et al. Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis. Neurology. 1999;53:1397-1401.
39. Aharoni R, Teitelbaum D, Leitner O, et al. Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1. Proc Natl Acad Sci USA. 2000;97:11472-11477.
40. Sormani MP, Bruzzi P, Comi G, Filippi M. MRI metrics as surrogate markers for clinical relapse rate in relapsing-remitting MS patients. Neurology. 2002;58:417-421.
41. Walther EU, Hohlfeld R. Multiple sclerosis: Side effects of interferon beta therapy and their management. Neurology. 1999;53:1622-1627.
42. Sorenson PS, Koch-Henriksen N, Ross C, et al. Neutralizing antibodies against interferon (IFN)-beta reduce the clinical effect in relapsing-remitting multiple sclerosis [abstract]. Mult Scler. 2002;8(Suppl 1):S8.
43. Bertolotto A, Malucchi S, Milano E, et al. Interferon β neutralizing antibodies in multiple sclerosis: Neutralizing activity and cross-reactivity with three different preparations. Immunopharmacology. 2000;48:95-100.
44. Ziemssen T, Neuhaus O, Hohlfeld R. Risk-benefit assessment of glatiramer acetate in multiple sclerosis. Drug Saf. 2002;24:979-990.
45. Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2003;348:15-23.
46. Vollmer T, Durkalski V, Tyor W, et al. An open-label, single arm study of simvastatin as a therapy for multiple sclerosis (MS) [abstract]. Neurology. 2003;60(Suppl 1):A84.
47. Lublin F, Baier M, Cutter G, et al. Results of the extension of a trial to assess the longer term safety of combining interferon beta-1a and glatiramer acetate [abstract]. Neurology. 2002;58(Suppl 3):A85.
48. First DataBank [database]. San Bruno, Calif: 2003. Updated October 23, 2003.
49. O'Brien J, Patrick A, Duran P, et al. The economic burden of relapse in multiple sclerosis: Direct medical costs per episode in the United States [abstract]. Mult Scler. 2002;8 (Suppl 1):S115.
50. Grudzinski AN, Hakim Z, Cox ER, et al. The economics of multiple sclerosis: Distribution of costs and relationship to disease severity. Pharmacoeconomics. 1999;15:229-240.
51. Whetten-Goldstein K, Sloan F, Goldstein LB, et al. A comprehensive assessment of the cost of multiple sclerosis in the United States. Mult Scler. 1998;4:419-425.
52. Minden SL, Marder WD, Harrold LN, et al. Multiple Sclerosis: A Statistical Portrait. A compendium of data on demographics, disability and health services utilization in the United States. Prepared for the National Multiple Sclerosis Society. Cambridge, Mass: Abt Associates, Inc; 1993.
53. Grudzinski AN, Hakim A, Cox ER, et al. Economic assessment of the relationship between disease exacerbations and the cost of multiple sclerosis. J Managed Care Pharm 2000;6:19-24.
54. Gautier S, Bachelet H, Bordet R, et al. The cost of adverse drug reactions. Expert Opin Pharmacother. 2003;4:319-326.
55. Candpolit MWN, Riise T, Kjell-Morten M, et al. Quality of life in multiple sclerosis: Measuring the disease effects more broadly. Neurology. 1999;53:1098-1103.
56. Vickrey BG, Edmonds ZV, Shatin D, et al. General neurologist and subspecialist care for multiple sclerosis: Patients' perceptions. Neurology. 1999;53:1190-1197.
57. Burks J. Multiple sclerosis care: An integrated disease-management model. J Spinal Cord Med. 1998;21:113-116.
58. Vickrey BG, Shatin D, Wolf SM, et al. Management of multiple sclerosis across managed care and fee-for-service systems. Neurology. 2000;55:1341-1349.
59. Weis R, Stamm K, Smith C, et al. Communities of care and caring: The case of MSWatch.com. J Health Psychol. 2003;8:135-148.